- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| KADIMASTEM Aktie jetzt für 0€ handeln | |||||
| 31.03. | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement | 300 | ACCESS Newswire | The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd.(NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage... ► Artikel lesen | |
| 10.03. | NLS Pharmaceutics kündigt Fusion mit Kadimastem an | 2 | Investing.com Deutsch | ||
| 25.02. | NLS Pharmaceutics Ltd.; Kadimastem Ltd.: Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment | 179 | PR Newswire | Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH and NESS ZIONA, Israel... ► Artikel lesen | |
| 10.02. | NLS und Kadimastem planen Fusion für Innovation in der Diabetesbehandlung | 1 | Investing.com Deutsch | ||
| 31.01. | NLS Pharmaceutics Stock Rises 29% Following Merger Announcement With Kadimastem | - | RTTNews | ||
| 31.01. | Kadimastem gets shareholder backing for NLS merger, advancing once-thwarted push for Nasdaq listing | 1 | FierceBiotech | ||
| 31.01. | NLS and Kadimastem move forward with merger plans | 1 | Investing.com | ||
| 31.01. | Kadimastem Ltd.: Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics | 796 | PR Newswire | ZURICH and NESS ZIONA, Israel, Jan. 31, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| 30.12.24 | NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger | 471 | PR Newswire | The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and a focus on advancing its allogeneic cell therapy platform... ► Artikel lesen | |
| 19.12.24 | NLS Pharmaceutics und Kadimastem streben Fusion im Januar an | 3 | Investing.com Deutsch | ||
| 19.12.24 | NLS Pharmaceutics and Kadimastem eye January merger | 5 | Investing.com | ||
| 19.12.24 | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment | 311 | ACCESS Newswire | This submission comes after successful INTERACT meeting with the FDA earlier this year.NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025 ZURICH, SWITZERLAND AND NESS... ► Artikel lesen | |
| 05.11.24 | NLS Pharmaceutics and Kadimastem stocks soar following merger agreement | 1 | Pharmaceutical Technology | ||
| 04.11.24 | NLS Pharmaceutics und Kadimastem fusionieren in Biotech-Deal | 1 | Investing.com Deutsch | ||
| 04.11.24 | NLS Pharmaceutics stock rallies 48% on merger agreement with cell therapy developer Kadimastem | 3 | Seeking Alpha | ||
| 04.11.24 | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement | 446 | ACCESS Newswire | ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA") ("Kadimastem")... ► Artikel lesen | |
| 29.07.24 | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge | 396 | ACCESS Newswire | The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy... ► Artikel lesen | |
| 18.07.24 | Pluri Inc.: Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates | 751 | GlobeNewswire (Europe) | HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global... ► Artikel lesen | |
| 28.05.24 | IM Cannabis Corp.: IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market | 398 | PR Newswire | With Germany delivering accelerated growth after legalization, IMC is keeping all options open to maximize shareholder value
TORONTO and GLIL YAM, Israel, May 28, 2024 /PRNewswire/ --... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 23,480 | -36,02 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
| QIAGEN | 37,020 | -1,57 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| TEMPUS AI | 52,90 | -1,13 % | Tempus AI: Deal mit Pharma-Riesen - Aktie geht steil | Für den AKTIONÄR ist klar: Künstliche Intelligenz (KI) wird auch in der Forschung und Entwicklung von Medikamenten mittel- bis langfristig sein disruptives Potenzial entfalten. Ein Player, der diesen... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,860 | -2,10 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 50,000 | +0,06 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | ||
| SPRINGWORKS THERAPEUTICS | 44,740 | -0,42 % | SpringWorks Therapeutics-Aktie: Kommt die Übernahme? | Nachdem die SpringWorks Theraputics-Aktie bereits am Dienstag und Mittwoch in Summe um +11% zulegen konnte, schoss sie am Donnerstag um weitere +9% nach oben. Was steckt hinter der starken Kursperformance... ► Artikel lesen | |
| EVOTEC | 7,382 | +0,52 % | Das ist die Nach-Oster-Chance! Evotec, Bayer, BioNTech, Defence Therapeutics und im Fokus | Donald Trump brüskiert seine internationalen Partner, beleidigt namhafte Amerikaner und entzieht Harvard langjährig zugesagte Fördermittel. Wer hätte das gedacht? Die neue US-Regentschaft entpuppt sich... ► Artikel lesen | |
| BIONTECH | 102,10 | -0,10 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
| DYNE THERAPEUTICS | 11,060 | -0,45 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy | - Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 29,610 | +0,61 % | JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? | ||
| VERVE THERAPEUTICS | 5,760 | -0,35 % | Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 | Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,740 | -0,17 % | Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? | ||
| VIR BIOTECHNOLOGY | 6,120 | -2,70 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data... ► Artikel lesen | |
| CG ONCOLOGY | 22,400 | +4,09 % | CG Oncology Inc.: CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting | ||
| AVIDITY BIOSCIENCES | 30,860 | -0,23 % | Avidity Biosciences Inc Aktie: Routinebericht des Unternehmens | Avidity Biosciences hat die Rekrutierung für die Biomarker-Kohorte der Phase-1/2-FORTITUDE-Studie für Delpacibart Braxlosiran (Del-Brax) abgeschlossen. Diese Studie zielt auf Patienten mit fazioskapulohumeraler... ► Artikel lesen |
KADIMASTEM LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KADIMASTEM LTD finden Sie auf Wallstreet Online.
